Biofrontera Inc. Q1 FY2026 earnings call

• Business Model Transformation: The October 2025 strategic transaction with BioFrontera AG gave BioFrontier Inc. full ownership and control of all U.S. rights, approvals, patents, and manufacturing for Ameluz and RotoLED, with the FDA formally transferring all regulatory filings in December 2025. The new 12-15% tiered earn-out structure replaced the previous 25-35% transfer pricing model, driving the gross margin expansion seen in Q1 2026. Cash used in operations dropped dramatically from $4.1 million in Q1 2025 to just $70,000 in Q1 2026, putting the company on track to hit cash flow breakeven in 2026.
• Clinical & Regulatory Progress: 1) For superficial basal cell carcinoma (SBCC), the FDA accepted the company's supplemental New Drug Application (sNDA) for Ameluz PDT in February 2026, with a PDUFA target action date of September 28, 2026. If approved, Ameluz will become the first PDT drug approved to treat cancer in the U.S. 2) For actinic keratosis (AK) on the extremities, neck, and trunk, the company announced positive statistically significant top-line Phase III results meeting the primary endpoint in February 2026, supporting a planned sNDA filing in Q3 2026 that will expand the approved label beyond face and scalp to treatment fields up to 240 square centimeters, opening a large new addressable market. 3) For moderate to severe acne vulgaris, Q1 2026 Phase II results showed a 58% reduction in inflammatory lesions for Ameluz (vs 37% for vehicle gel) with 86% patient satisfaction, and the company plans to discuss Phase III trial design with the FDA in H2 2026.
• Commercial Execution: The company's focused commercial strategy centered on increased accountability, refined customer segmentation, AI-assisted data targeting, and expanded in-person sales activity has driven sustained volume growth. Lower sales force turnover compared to Q1 2025 has improved territory performance, and the Q4 2025 inside sales pilot for undercovered territories and smaller accounts was fully rolled out in Q1 2026 and is already delivering positive results.
• Corporate Milestone: In May 2026, BioFrontier regained compliance with NASDAQ's minimum $1 per share bid price requirement after meeting the 10 consecutive trading day rule, ending its prior non-compliance status.

BioFrontier operates with two core product segments: Ameluz (photodynamic therapy drug) and RotoLED (treatment lamps). In Q1 2026, total product revenue reached $10.1 million, a 17% year-over-year (YoY) increase from $8.6 million in Q1 2025. Ameluz contributed ~97% of total revenue: Ameluz unit volumes grew 16% YoY from 25,000 tubes to 29,000 tubes in Q1 2026, with a Q4 2025 price hike adding $0.2 million in incremental revenue. The RotoLED lamp segment shipped 32 units in Q1 2026, bringing the total installed base to 773 units across 709 dermatology offices as of March 31, 2026. Cost of revenue decreased 40% YoY from $3.1 million to $1.8 million, and the new earn-out structure dropped cost of revenue as a share of product revenue significantly from the prior 25% transfer pricing level. Gross margin for the combined business expanded to 80% in Q1 2026 from 62% in Q1 2025, tracking toward the company's 80%-85% long-term target.

• Management reaffirmed the full-year 2026 target of reaching cash flow breakeven, driven by sustained revenue growth, the full impact of the new lower-cost structure from the BioFrontera AG strategic transaction, and disciplined expense management.
• Gross margin is expected to stay within the 80% to 85% target range for the remainder of 2026, with minor fluctuations possible based on product mix between Ameluz and RotoLED sales and discounting adjustments, which management notes is manageable.
• SG&A operating run rate is not expected to change drastically for the remainder of 2026, with some normal seasonality in cash usage expected through the year.
• Key upcoming clinical/commercial milestones are confirmed: sNDA filing for expanded AK indication in Q3 2026, PDUFA decision for SBCC approval in September 2026, initial SBCC launch rollout in Q4 2026 with full acceleration in Q1 2027, and FDA discussions for acne Phase III design in H2 2026.

• The company's financial statements still include a going concern qualification; while the company has made strong progress toward cash flow breakeven, current cash reserves ($6.3 million as of March 31, 2026) require balanced expansion of commercial operations and expense control. If revenue growth falls short of expectations, management may need to secure additional working capital via a line of credit or other financing to continue operations.
• All BioFrontier products are exclusively imported from Europe, so the company is exposed to potential impacts from newly imposed global tariffs on imports from certain regions, which could affect supply chains, product costs, and require changes to pricing strategy.
• Clinical trial and regulatory outcomes carry inherent uncertainty: FDA feedback on acne trial design could require additional Phase II testing that would delay development, and the SBCC sNDA approval is not guaranteed as of the call.
• Off-label use of Ameluz is not encouraged by the company, and current low off-label use is partially driven by payer refusal to reimburse off-label treatment, creating a constraint on unlabeled market adoption until label expansions are approved.
• The company faces ongoing patent-related legal claims that have increased legal expenses and created discrete non-recurring costs, including $0.4 million in patent remediation expense recorded in Q1 2026.

Q: What is the current scale of off-label use of Ameluz for AK on extremities, neck, and trunk, and what is the path for future acne clinical development? / A: Management confirms there is only small current off-label use, as most payers refuse to reimburse off-label treatment and doctors avoid off-label use, and BioFrontier only markets Ameluz for its approved on-label indications. For acne development, management does not expect additional Phase II trials are needed, as existing Phase II data meets requirements and aligns with results for top competing topical products. The final path will be confirmed in discussions with the FDA in H2 2026.

Q: If the SBCC sNDA is approved in September 2026, is BioFrontier prepared to launch immediately, or is additional preparation required? / A: The company has already completed all required preparation for an SBCC launch, and is actively prepping for commercialization ahead of the PDUFA date. Initial rollout with the medical team and limited commercial launch will begin in Q4 2026, with full commercial acceleration planned for Q1 2027 immediately after approval.

Q: Is the Q1 2026 SG&A run rate sustainable for the rest of 2026, and are there additional one-time costs that will drop off? / A: Management notes there is normal seasonality in operating cash flow, but does not expect the SG&A run rate to change drastically for the full year. The company remains on track to hit its full-year 2026 cash flow breakeven target despite seasonal swings.

Q: Can management confirm if gross margin will stay near the Q1 2026 80% level for the rest of the year, as the company moves toward its long-term target? / A: Management confirms it is very achievable to maintain gross margin within the 80% to 85% target range for the full year. Minor fluctuations may occur based on product sales mix between Ameluz and RotoLED and group purchasing organization discount adjustments, but management notes these variables are manageable.